Portal de investigación
OPTIMIZACION DEL TRATAMIENTO DE LA ANEMIA FERROPENICA SECUNDARIA A HEMORRAGIA DIGESTIVA AGUDA. COMPARACION DE DOS ESTRATEGIAS (HIERRO INTRAVENOSO VS. ORAL)
Datos básicos
- Código:
- FERRO
- Protocolo:
- FERRO
- EUDRACT:
- 2009-016847-20
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers.
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.3748/wjg.v29.i7.1139. 2023
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Association between Chronotype, Physical Activity and Sedentary Behaviour: A Systematic Review
Sempere-Rubio, Nuria, Aguas, Mariam, Faubel, Raquel
Article. 10.3390/ijerph19159646. 2022
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Calafat, Margalida; (...); Domenech, Eugeni
Article. 10.1177/17562848231221713. 2024
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry
Madero Velazquez, L.; (...); Gutierrez-Casbas, A.
Meeting Abstract. 2024
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
Aguas Peris, M.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0428. 2025
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.1016/j.gastrohep.2021.08.006. 2021
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
Del Hoyo Francisco, J.; (...); Aguas, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.758. 2021
Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources
Sempere Robles, L.; (...); Ruiz, M. T.
Article. 2022
Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown
Sempere Robles, L.; (...); van-der Hofstadt, C.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.270. 2021
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2024
Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2023
Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Garcia, M. J.; (...); Chaparro, M.
Meeting Abstract. 2023
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
Garcia, Maria Jose; (...); Chaparro, Maria
Article. 10.1111/apt.17938. 2024
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Article. 10.1016/j.gastrohep.2023.12.001. 2024
Evolution of the emotional impact in patients with early inflammatory bowel disease during and after Covid-19 lockdown.
Sempere L; (...); Hofstadt CV
Article. 10.1016/j.gastrohep.2021.03.004. 2021
Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics project.
Orejudo, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Gender Biases and Diagnostic Delay in Inflammatory Bowel Disease: Multicenter Observational Study.
Sempere L; (...); Ruiz-Cantero MT
Article. 10.1093/ibd/izad001. 2023
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.
Gutiérrez A; (...); Francés R
Article. 10.3389/fmed.2022.823900. 2022
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
Chaparro, Maria; (...); Gisbert, Javier P.
Article. 10.3390/jcm10132885. 2021
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis.
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Article. 10.1002/jca.22101. 2023
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Novel biomarkers associated with inflammatory bowel disease
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world
Minguez, A.; (...); Bastida, G.
Meeting Abstract. 2024
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
Minguez, Alejandro; (...); Bastida, Guillermo
Article. 10.1016/j.gastrohep.2024.502253. 2024
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease.
Calvo Moya M; (...); Gutiérrez Casbas A
Article. 10.1016/j.gastrohep.2023.12.013. 2024
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease
Soleto, I.; (...); Chaparro, M.
Meeting Abstract. 2023
Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery
Baldan-Martin, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients.
Bernabeu P; (...); Sempere L
Article. 10.3389/fpsyg.2024.1334308. 2024
Psychological burden in newly diagnosed IBD patients: Differences between Crohn's Disease and Ulcerative Colitis in early IBD
Bernabeu, P.; (...); Sempere, L.
Article. 2022
Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2023
Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease.
Huguet, JM; (...); Paredes, JM
Article. 10.12998/wjcc.v9.i36.11285. 2021
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
Iborra, Marisa; (...); Nos, Pilar
Article. 10.1080/00365521.2023.2278427. 2023
Real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA Registry
Barreiro-de Acosta, M.; (...); Ferreiro-Iglesias, R.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0783. 2025
Recommendations of the Valencian Society of Digestive Pathology for the use of telemedicine and non-contact consultations.
Jover, Rodrigo; (...); Nos, Pilar
Article. 10.1016/j.gastrohep.2021.04.009. 2022
Role of Interleukin-8 in Predicting Long-Term Response to Vedolizumab in Ulcerative Colitis Patients
Minguez, A.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1111. 2025
Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naive Inflammatory Bowel Disease Patients
Aldars-Garcia, Laila; (...); Chaparro, Maria
Article. 10.1093/ibd/izad154. 2024
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
Chaparro, M.; (...); ECCO CONFER Taskforce
Meeting Abstract. 2022
Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]
Chaparro, Maria; (...); Julsgaard, Mette
Article. 10.1093/ecco-jcc/jjac050. 2022
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Telemonitoring with TECCU of active Inflammatory Bowel Disease is Not Inferior to Standard Care: Short-term Results of a Multicentre Randomized Controlled Trial of GETECCU.
Article. 10.2196/60966. 2024
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
Ladron Abia, Pablo; (...); Iborra, Marisa
Article. 10.1016/j.gastrohep.2022.01.004. 2022
The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making
Bastida Paz, Guillermo; (...); Nos, Pilar
Article. 10.1159/000531789. 2023
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response
Minguez, A.; (...); Nos, P.
Meeting Abstract. 2023
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFalpha used for the treatment of IBD: Results from the VERNE study.
Bastida G; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2021.06.005. 2021
Ustekinumab as an opportunity for refractory Ulcerative Colitis patients
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2022
Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients
Mateos, B.; (...); Beltran, B.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.697. 2021
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023